ReviewExpert reviews in molecular medicine2011
Oncolytic virotherapy for pancreatic cancer.
Review in Expert reviews in molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Oncolytic viruses: A novel therapeutic approach for pancreatic cancer.Molecular therapy. Oncology · 2025Review
- Review
- A Cellular Automata Model of Oncolytic Virotherapy in Pancreatic Cancer.Bulletin of mathematical biology · 2020Article
- Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus.Oncology letters · 2019Article
- NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses-Therapeutic Perspectives.Cancers · 2018Review
- Molecular characterization and expression of a disintegrin and metalloproteinase with thrombospondin motifs 8 in chicken.Asian-Australasian journal of animal sciences · 2018Article
- Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.Journal of virology · 2017Article
- Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.International journal of molecular sciences · 2017Review
- Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Oncotarget · 2016Article
- Viro-immune therapy: A new strategy for treatment of pancreatic cancer.World journal of gastroenterology · 2016Review
- AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.Molecular cancer · 2015Article
- Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.Human gene therapy · 2015Article
- Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.Journal of virology · 2014Article
- Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.Journal of virology · 2014Article
- Advanced-stage pancreatic cancer: therapy options.Nature reviews. Clinical oncology · 2013Review
- Article
- Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model.Journal of virology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas the applicability of other more recently investigated OVs, such as poxviruses and parvoviruses, is only starting to be determined. At the same time, studies have identified key characteristics of pancreatic cancer biology that provide a better understanding of the important factors or pathways involved in this disease. This review aims to summarise the different replication-competent OVs proposed as therapeutics for pancreatic cancer. It also focuses on the unique biology of these viruses that makes them exciting candidate virotherapies for pancreatic cancer and discusses how they could be genetically manipulated or combined with other drugs to improve their efficacy based on what is currently known about the molecular biology of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.